ADMA Biologics Inc vs NIO Inc. — how do they compare? ADMA Biologics Inc trades at $9.86 (market cap $2.22B), while NIO Inc. trades at $4.55 (market cap $11.59B). The key difference: NIO Inc. is far larger — about 5.2× ADMA Biologics Inc's market cap, and ADMA Biologics Inc is trading nearer its 52-week high, NIO Inc. nearer its low. Which is the better fit depends on your goals.
| ADMA | NIO | |
|---|---|---|
Market Cap | $2.22B | $11.59B |
Sector | Health | Consumer Cyclical |
52-Week High | $20.38 | $7.89 |
52-Week Low | $7.60 | $4.44 |
Enterprise Value | $2.29B | $10.82B |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
NIO's stock trades at $4.575, down 5.08% amid bearish technical signals and negative cash flows. Revenue grew to $87.49 billion in 2025, but net losses persist at -$15.57 billion. Recent news highlights delivery growth and competitive pressures in China's EV market, with shares near support levels after a steep decline from 2026 highs.
The outlook remains challenged by profitability concerns and high debt, though analyst consensus leans bullish with 54% buy ratings. Key risks include intense competition and reliance on financing, while potential upside hinges on margin improvement and sustained delivery growth in a volatile sector.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →